1. Janssen Biotech Inc. Darzalex™ (daratumumab): prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036s000lbl.pdf . Accessed 17 Dec 2015.
2. Genmab AS. Genmab enters worldwide agreement with Janssen for daratumumab [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=703394 . Accessed 17 Dec 2015.
3. Phipps C, Chen Y, Gopalakrishnan S, et al. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015;6(3):120–7.
4. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8.
5. US Food and Drugs Administration. FDA approves Darzalex for patients with previously treated multiple myeloma. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472875.htm . Accessed 17 Dec 2015.